Short answer: a kratom lab report, usually called a certificate of analysis or COA, is a test sheet for one batch of product. It helps you check the alkaloid amounts and contaminant screens for that batch, but only when the lot number on the report matches the package you’re holding. It can’t tell you whether kratom is safe for you, whether it does anything for you, or whether it’s legal where you live.
Kratom is not FDA approved for any use. The FDA says it is not lawfully marketed in the U.S. as a drug product, a dietary supplement, or a food additive in conventional food, and FDA’s kratom page sets out that position. A lab result doesn’t change that status, so read any report with it in mind.
What a kratom lab report should list
Kratom’s chemistry centers on its alkaloids. The DEA kratom profile says at least 54 alkaloids have been isolated from the plant. It says mitragynine is the most abundant, at about 66% of total alkaloid content, and 7-hydroxymitragynine (7-OH) is a minor alkaloid at under 2%. It also says alkaloid content varies significantly with plant strain and maturity. A useful report shows these amounts for your batch. One seller’s COA checklist asks you to look for the items below.
| What to check | What to look for | Why it matters |
|---|---|---|
| Lot or batch number | Matches the number printed on your package | The report describes one batch |
| Testing lab | The lab’s name and the report date | You know who ran the test and whom to ask |
| Mitragynine amount | Lines up with the amount on the label | The seller’s checklist asks for this match |
| 7-OH amount | Listed separately from mitragynine | In natural leaf, FDA puts 7-OH under 2% of total alkaloid content |
| Contaminant screens | Heavy metals, pesticides, microorganisms and synthetic substances | A European seller’s guide names these as the contaminants testing should cover |
| Confirmation method | Mass spectrometry named, such as LC-MS/MS | Mass spectrometry identifies specific compounds |
A report showing a 7-OH share well above that 2% figure is describing a different kind of product from leaf. Leaf, extracts and 7-OH products need their own reports, and one report doesn’t stand in for another.
Why the lot number has to match your package
A COA describes the batch that was tested, not the brand name on the bag or bottle. Because alkaloid content varies with plant strain and maturity, another lot can look different on paper. Match the lot or batch number printed on your package to the report, line by line. If the numbers don’t match, the report describes a different batch, even if its figures look right.
What a lab report can’t tell you
- Safety. The NCCIH kratom overview says the long-term effects of kratom use are not well understood. It lists mild effects such as nausea, constipation, dizziness and drowsiness, and rare but serious effects such as seizures, high blood pressure and liver problems. It also says fatal overdoses from kratom alone appear to be extremely rare, while combining kratom with other drugs has been linked to deaths. A COA doesn’t measure any of that in your body.
- Effect. NCCIH says research on kratom is in its early stages and that kratom has not been shown to be safe and effective for this or any other medical use.
- Legal status. The DEA says kratom itself remains an unscheduled botanical and is not a controlled substance under the Controlled Substances Act. State and local rules differ, so check the rules where you live and where the product ships.
- A drug test result. A COA is not a drug test. Whether a drug test finds kratom depends on the test.
Will kratom show up on a drug test?
Usually, a standard panel won’t look for it. A specialized test can, but only when the lab was asked to run it.
| Test type | Looks for kratom by default? | What to know |
|---|---|---|
| Standard panel (5-panel, 10-panel) | No, according to one seller’s guide | Read the analyte list, because a panel’s name doesn’t list its contents |
| Immunoassay screen | Only for the targets on its list | A positive screen needs confirmation |
| Specialized mitragynine assay (screen and confirmation) | Yes, that is its purpose | Ordered separately; used in clinical, rehab or legal settings |
| Probation, court or treatment monitoring | Only if the order includes kratom | Monitoring may use a customized list |
Does kratom show up on a 10-panel test?
Not on a standard one, as far as published panel descriptions go. One seller’s guide puts it plainly: a “10-panel” means about ten categories were packaged, not that kratom is one of them. If kratom or mitragynine is named on your paperwork, ask for the assay name in writing.
For a 12-panel test, the name alone won’t tell you what’s on it. Read the analyte list on your order before you assume either way.
Keep one distinction in mind. “Not detected” means the test looked and didn’t find it. “Not tested” means the test never looked for it. A negative result on a panel that doesn’t list mitragynine says nothing about kratom.
Do DOT drug tests test for kratom?
A DOT-style five-panel test follows a fixed set of categories under federal rules, and mitragynine isn’t a default analyte on those published panels, according to one seller’s guide. Employers can add to the list. Ask your employer or the collector for the exact panel in writing.
What does a positive immunoassay mean?
An immunoassay is a screen. It looks for specific targets on its list, and a positive result is a flag, not a final answer. The same seller’s guide says that if something unexpected shows up on an initial screen, you should request confirmatory testing, because mass spectrometry identifies specific compounds.
Does kratom show up as an opiate?
One seller’s guide says mitragynine is structurally distinct from the morphine-class opioids that standard immunoassays target, and that routine cross-reactivity is not how those panels are designed to work. That is the seller’s statement. If an opiate result comes back, ask for confirmation so the compound is named.
Does LabCorp check for kratom?
One seller’s guide points to a Labcorp menu item called Kratom (Mitragynine), Screen and Confirmation, Urine panel. It is ordered separately from standard panels. Check Labcorp’s current test menu, or ask the clinician who would order it.
Will kratom show up on a toxicology report or a probation test?
A toxicology report shows the analytes that were ordered. Specialized kratom detection uses methods such as GC-MS or LC-MS/MS, and one seller’s guide says these are typically used in legal, clinical or rehab settings. Probation, parole and court-ordered monitoring can use customized lists, so the order paperwork decides what is tested.
How long does kratom stay in your system for a urine test?
There is no single window. Dose, how often you use it, metabolism, the type of sample and the lab’s cutoff all change the result. One seller’s guide says exact hour-or-day claims are not trustworthy science. For a known specialized test, ask the ordering clinician.
Is kratom an opioid or a narcotic?
Kratom is not a federally controlled substance, but its main compounds act on opioid receptors. NCCIH says mitragynine and 7-hydroxymitragynine interact with opioid receptors in the brain. FDA says 7-OH demonstrates “substantially greater mu-opioid receptor potency than kratom’s primary alkaloid constituent mitragynine, as well as other classical opioids such as morphine.” That is why the opioid question matters for the product you’re considering.
What kratom effects do people report?
NCCIH says people who use kratom have reported both stimulant-like effects, such as increased energy, alertness and rapid heart rate, and opioid- and sedative-like effects, such as relaxation, pain relief and confusion. The DEA lists acute side effects that include nausea, itching, sweating, dry mouth, constipation, increased urination and loss of appetite. These are reports from people who used kratom, which is different from the controlled studies below.
For a fuller breakdown of reported kratom side effects, see our super speciosa side effects guide.
What the studies found
Most of the human research on kratom is recent and small, and each study tests one material. None of them tests the product you’re holding, so read the material column before you apply a finding to a store product.
| Study | Who took part | Material and length | What it found | Limit or caution in the study |
|---|---|---|---|---|
| Ther Drug Monit 2026 trial | 116 volunteers aged 18 to 55 (49 given the product, 67 placebo) | Dried kratom leaf powder (MitraLeaf); single doses, then 15 daily doses over 47 days | No serious adverse events or deaths. Side effects generally rose with dose. Dizziness, nausea and feeling of relaxation were most common after single doses; headache, feeling hot, raised ALT and nausea after daily doses | The authors concluded the product was well tolerated “at the dose ranges tested” |
| Drug Test Anal 2026 study | 116 healthy, kratom-naive adults (49 given the product, 67 placebo) | MitraLeaf capsules; single doses and 15 daily doses | Modest, dose-related subjective effects. No participant met the threshold for clinically meaningful opioid withdrawal on the COWS or SOWS scales. Side effects were generally mild | The authors say the findings support further research and stress dose control and product standardization |
| J Clin Psychopharmacol 2026 pilot | 40 recreational polydrug users with opioid experience, otherwise healthy | Botanical leaf kratom in single doses at escalating amounts | Somnolence, vomiting and nausea were the most common side effects. Pupils constricted at higher doses. The highest dose raised ratings of “drug liking” and “high” | The study was single-sourced and “may not be representative of other kratom-containing products” |
| Psychopharmacology 2025 study | 15 healthy volunteers in two parts | Mitragynine alone, not leaf powder; single doses, with 7 hours of monitoring | Most measures were unaffected. The lowest dose raised ratings of arousal and attention. The highest dose raised ratings of amnesia and produced mild psychopathological symptoms | Tested one alkaloid in healthy volunteers, so it doesn’t describe a leaf product |
| Kratom and drug interactions study | 12 healthy adults | A single low dose of kratom tea | A modest increase in midazolam levels, a CYP3A probe drug. No change in dextromethorphan, a CYP2D6 probe drug | The authors say co-consuming kratom with certain CYP3A-metabolized drugs “may precipitate serious interactions” |
A 2026 study in the Journal of Analytical Toxicology looked at a concentrated extract containing 39.5% mitragynine, given as single doses and as 15 daily doses. Its authors reported that concentrated extracts may yield greater overall mitragynine exposure than dried leaf powder or tea at comparable doses. Several of its authors are consultants to NP Pharma, and the paper says they were compensated for writing the manuscript.
FDA’s kratom page, last updated December 2, 2025, says a well-designed human abuse potential study had not yet been conducted, and that FDA awarded a grant for one in September 2024. That is the gap the 2026 studies above begin to address, and they still test specific products at specific doses.
What FDA and CDC data show about 7-OH and poison-center reports
Leaf, extracts and 7-OH are different products. CDC describes 7-OH as “a μ-opioid receptor agonist that is marketed as kratom but is distinct from traditional kratom leaf preparations.” FDA has issued warning letters to firms marketing products containing 7-hydroxymitragynine, and its 7-OH products page describes its actions against those products.
A October 14, 2026 Federal Register notice is a notice of intent. It proposes thresholds for 7-OH and MGPI. FDA’s 7-OH page describes the HHS-recommended thresholds as more than 1 milligram per gram in solid products, or a ratio of mitragynine to 7-OH, MGPI or their combined amount of less than 100 to 1. Read the notice itself for its exact wording.
CDC’s analysis of poison-center data counts 14,449 kratom exposure reports from 2015 through 2025, including 3,434 in 2025, up from 258 in 2015. These are reports to poison centers, not a count of harm among all kratom users. CDC also notes that the data do not include information about whether the kratom use involved traditional leaf products or semisynthetic or concentrated formulations, and that the reports are voluntary.
Who should talk to a clinician first
If you are pregnant or nursing, take prescription medicine, have liver disease, or have a history of substance use, talk with a clinician before you use kratom or agree to a test. This is the one safety note that matters most here.
The reasons are in the sources. The CDC says kratom use with alcohol, opioids, benzodiazepines, stimulants and antidepressants might increase risk. NCCIH lists liver problems among the rare but serious effects. NCCIH also says kratom itself may have the potential to be addictive, and that regular users may have withdrawal symptoms if they stop. If that applies to you, read about kratom withdrawal and how to get medical help.
Before you order
- Check that the lot number on the COA matches the number on your package.
- Check that the report names the testing lab, lists mitragynine and 7-OH separately, and shows contaminant screens.
- Read the label for the ingredient list, warnings and age limits.
- Get the seller’s return terms in writing before you pay.
- Ask the lab or your program which analytes are on your order.
- State and local rules differ, so check yours before you buy or travel with a product.
By HealthDataConsortium.org Research Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.

